Understanding Unresectable Stage III NSCLC: A Radiation Oncologist’s Perspective

For the past several decades, the combination of radiation and chemotherapy has been the standard of care for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC).¹ Although the advances in radiation have shown some benefits, additional treatment options are needed for eligible patients.^2,3 That’s why this live broadcast features radiation oncologist Dr Roy Decker, who shares data on a treatment option for unresectable Stage III NSCLC.

References:

1. Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicans evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e314s-e340S.
2. Ahn JS, Ahn YC, Kim JH, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer. KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660-2666.
3. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007;25(13):1698-1704.

Sponsored by:   

©2021 AstraZeneca. All rights reserved. US-58430 Last Updated 10/21